The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | CTCL management: the challenges faced by clinicians
Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, discusses the challenges faced by clinicians during the management of cutaneous T-cell lymphoma (CTCL), which consists of different entities, and suggests approaches to reduce the effects of these setbacks. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Transcript
The challenges faced by clinicians and the management of these patients are many. The first thing is a cutaneous T-cell lymphoma is not one entity. It’s many different conditions, some of which are quite indolent, some of which are extremely aggressive. A clinician that doesn’t encounter these entities very commonly may have a lot of difficulty parsing out the differences, and even knowing that some of these entities exist to be honest...
The challenges faced by clinicians and the management of these patients are many. The first thing is a cutaneous T-cell lymphoma is not one entity. It’s many different conditions, some of which are quite indolent, some of which are extremely aggressive. A clinician that doesn’t encounter these entities very commonly may have a lot of difficulty parsing out the differences, and even knowing that some of these entities exist to be honest. That would be the first challenge. Going along with that, if you have not had a lot of experience with different entities, and there are diagnostic complexities to the different entities, so that you might not even have a clear idea what the diagnosis is for a given patient, it makes it that much more difficult to select the appropriate treatment for a given patient. I think that there are a tremendous amount of complexities in these situations with people with cutaneous T-cell lymphoma, and it’s very difficult, especially difficult for clinicians that aren’t focused in this area really to choose what the best treatment might be for their patient, and to really understand what the outlook is for a particular patient.
Read more...
